EPRX — EUPRAXIA PHARMACEUTICALS INC
As of Q2 2026, 13 SEC-registered investment managers reported holding EPRX (EUPRAXIA PHARMACEUTICALS INC) in their latest 13F filings, with a combined reported value of $28.45M across 4.30M shares. That is +12.2% by share count (+468.74K shares) versus the previous quarter, while reported value moved +2.5%. Ownership is concentrated: the five largest holders account for 82.3% of reported value and the top ten for 99.5%.
Compared with the prior quarter, 3 opened new positions, 4 added to existing stakes, 4 trimmed. 13F holdings are quarter-end snapshots, so these moves reflect positioning as of Q2 2026, not real-time trading.
EPRX is classified in the Health Care sector.
All figures on this page are computed from SEC Form 13F quarterly filings. 13F filers disclose long positions of $100,000 or more within 45 days of quarter end; short positions, options overlays and intra-quarter trades are not included, so treat the numbers as a quarterly snapshot of institutional ownership rather than real-time positioning.
| Fund | Quarter | Shares | Value | Portfolio Weight | Change |
|---|---|---|---|---|---|
| Balyasny Asset Management history | Q2 2026 | 1.35M | $8.92M | 0.01% | Hold |
| Point72 Asset Management history | Q2 2026 | 730.28K | $4.83M | 0.01% | Reduce |
| UBS Group AG history | Q2 2026 | 519.21K | $3.43M | 0.00% | Reduce |
| Citadel Advisors history | Q2 2026 | 502.01K | $3.32M | 0.00% | Add |
| Millennium Management history | Q2 2026 | 441.59K | $2.92M | 0.00% | New |
| Arrowstreet Capital history | Q4 2025 | 278.06K | $2.09M | 0.00% | New |
| Bank of America Corp history | Q2 2026 | 264.72K | $1.75M | 0.00% | Reduce |
| Two Sigma Investments history | Q2 2026 | 221.08K | $1.46M | 0.00% | Add |
| Marshall Wace history | Q2 2026 | 158.13K | $1.05M | 0.00% | Hold |
| Goldman Sachs Group history | Q2 2026 | 58.06K | $383.76K | 0.00% | Add |
| Geode Capital Management history | Q2 2026 | 36.21K | $239.35K | 0.00% | Add |
| JPMorgan Chase & Co history | Q2 2026 | 14.19K | $93.49K | 0.00% | New |
| BlackRock Inc history | Q2 2026 | 6.09K | $40.24K | 0.00% | New |
| Morgan Stanley history | Q2 2026 | 2.20K | $14.54K | 0.00% | Reduce |
New Positions (Q2 2026)
- Millennium Management 441.59K sh · $2.92M
- JPMorgan Chase & Co 14.19K sh · $93.49K
- BlackRock Inc 6.09K sh · $40.24K
Fully Exited (vs previous quarter)
No tracked fund fully exited this quarter.
Fund Position History — shares by quarter (top 14 funds)
| Fund | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Balyasny Asset Management | — | — | — | — | — | 1.35M | 1.35M | 1.35M | 1.35M |
| Point72 Asset Management | — | — | — | — | — | — | 712.10K | 967.58K | 730.28K |
| UBS Group AG | 29.59K | 33.00K | 28.00K | 51.20K | 37.50K | 95.76K | 220.02K | 762.63K | 519.21K |
| Citadel Advisors | — | — | — | 12.05K | 18.24K | — | — | 230.18K | 502.01K |
| Millennium Management | — | — | 10.00K | — | — | — | — | — | 441.59K |
| Bank of America Corp | — | — | — | 2.50K | 12.56K | 45.58K | 253.32K | 268.22K | 264.72K |
| Two Sigma Investments | — | — | — | — | — | — | — | 10.80K | 221.08K |
| Marshall Wace | — | — | — | — | — | — | 158.13K | 158.13K | 158.13K |
| Goldman Sachs Group | — | 34.50K | 34.50K | 34.50K | 39.80K | 40.10K | 58.06K | 53.08K | 58.06K |
| Geode Capital Management | — | — | — | — | — | — | 13.90K | 25.61K | 36.21K |
| JPMorgan Chase & Co | 1.89K | — | — | 2.70K | 18.72K | 16.47K | — | — | 14.19K |
| BlackRock Inc | — | — | — | — | — | — | — | — | 6.09K |
| Morgan Stanley | — | — | — | — | — | — | — | 8.82K | 2.20K |
| Arrowstreet Capital | — | — | — | — | — | — | 278.06K | — | — |
▲ Bought Low (fund opened/added, stock rose ≥5% next quarter) ▼ Sold High (fund reduced, stock fell ≥5% next quarter)
Drag / scroll to zoom · Default shows the most recent year · Annotations come from quarterly fund actions in 13F filings · Hover a marker for details